dapsone has been researched along with Autoimmune Thrombocytopenia in 35 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report describes a case of methemoglobinemia in association with dapsone therapy." | 7.73 | Methemoglobinemia associated with dapsone therapy in a child with pneumonia and chronic immune thrombocytopenic purpura. ( Roberts, WD; Schiff, DE; Sue, YJ, 2006) |
| "This report describes a case of methemoglobinemia in association with dapsone therapy." | 3.73 | Methemoglobinemia associated with dapsone therapy in a child with pneumonia and chronic immune thrombocytopenic purpura. ( Roberts, WD; Schiff, DE; Sue, YJ, 2006) |
| "5-(2-Pyridylsulfonyl)-2-thiazolamine (2) was effective both in mitomycin C (MMC)-induced thrombocytopenia and in an animal model of idiopathic thrombocytopenic purpura (ITP)." | 3.70 | Synthesis and effects of novel thiazole derivatives against thrombocytopenia. ( Manda, T; Matsuo, M; Nishigaki, F; Ogino, T; Sawada, M; Seki, N; Sudo, Y; Tsuji, K, 1998) |
| "Dapsone is an antibacterial sulfonamide with anti-inflammatory property, which showed therapeutic activity in patients with immune thrombocytopenia (ITP); the activity in patients who showed refractoriness to rituximab is unknown." | 2.77 | Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. ( Chiozzotto, M; Fanin, R; Marin, L; Puglisi, S; Volpetti, S; Zaja, F, 2012) |
| "Eight patients with idiopathic thrombocytopenic purpura (ITP) refractory to corticosteroids were given oral diaminodiphenyl sulfone (DDS) (75 mg to 150 mg/day)." | 2.69 | [Diaminodiphenyl sulfone therapy for refractory idiopathic thrombocytopenic purpura--long-term effectiveness and possible mechanisms]. ( Chiba, S; Hirasawa, A; Kawabuchi, Y; Nishikawa, T; Sato, T; Wakabayashi, Y, 1999) |
| "With prolonged life expectancy, immune thrombocytopenia (ITP) is frequent in elderly people." | 2.53 | How we manage immune thrombocytopenia in the elderly. ( Godeau, B; Mahévas, M; Michel, M, 2016) |
| "Dapsone is an inexpensive drug with a well-established safety profile." | 2.49 | Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. ( Gooneratne, L; Rodrigo, C, 2013) |
| "Chronic Immune Thrombocytopenic Purpura (cITP) has become a field of multiple therapeutic assays." | 2.45 | [Treatment of chronic immune thrombocytopenic purpura. Looking for something better. Review]. ( Diez-Ewald, M; Vizcaíno, G; Vizcaíno-Carruyo, J, 2009) |
| " Side effects of steroids prohibits their long-term use and patients often have to be switched to other agents." | 1.51 | Is dapsone still relevant in immune thrombocytopenia in resource limited settings? ( Dalal, P; Gulia, M; Gupta, M; Tahlan, A, 2019) |
| "Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment." | 1.48 | Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice. ( Aboud, N; Depré, F; Mayer, B; Salama, A, 2018) |
| " Side effects occurred in 31% (n = 13) of patients, and required dapsone withdrawal in 22% (n = 9) or dosage reduction in 10% (n = 4) of the cases." | 1.46 | Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients. ( Audia, S; Berthier, S; Bonnotte, B; Estève, C; Guilhem, A; Leguy-Seguin, V; Nicolas, B; Samson, M, 2017) |
| "Dapsone is a safe and cheap second-line therapy for ITP with a response rate of about 50% (majority being CR)." | 1.42 | Dapsone for immune thrombocytopenic purpura in children and adults. ( Patel, AP; Patil, AS, 2015) |
| "Dapsone has been shown to be effective in treating immune thrombocytopenic purpura (ITP) in adults." | 1.38 | Dapsone treatment in a girl with severe chronic thrombocytopenic purpura. Does it work? Do not touch it! ( Nocerino, A; Passone, E; Pusiol, A; Tenore, A, 2012) |
| " Dapsone-related adverse events were mild and promptly reversed by treatment withdrawal." | 1.35 | Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. ( Annichino-Bizzacchi, JM; De Paula, EV; Fabri, DR; Orsi, FL; Ozelo, MC; Vancine-Califani, SM, 2008) |
| "Dapsone was continued in 20/33 responders for a median of 12." | 1.30 | Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. ( Bierling, P; Durand, JM; Godeau, B; Kaplanski, G; Oksenhendler, E; Roudot-Thoraval, F; Schaeffer, A; Tennezé, A, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (25.71) | 18.2507 |
| 2000's | 9 (25.71) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Tsuji, K | 1 |
| Ogino, T | 1 |
| Seki, N | 1 |
| Sawada, M | 1 |
| Sudo, Y | 1 |
| Nishigaki, F | 2 |
| Manda, T | 2 |
| Matsuo, M | 1 |
| Dalal, P | 1 |
| Gulia, M | 1 |
| Gupta, M | 1 |
| Tahlan, A | 1 |
| Bm, S | 1 |
| Toshniwal, M | 1 |
| Bhattacharya, M | 1 |
| Jakkal, D | 1 |
| Bartakke, SP | 1 |
| Sampagar, AA | 1 |
| Reddy, NA | 1 |
| Kangle, R | 1 |
| Colella, MP | 1 |
| Orsi, FA | 1 |
| Alves, ECF | 1 |
| Delmoro, GF | 1 |
| Yamaguti-Hayakawa, GG | 1 |
| de Paula, EV | 2 |
| Annichino-Bizzacchi, JM | 2 |
| Estève, C | 1 |
| Samson, M | 1 |
| Guilhem, A | 1 |
| Nicolas, B | 1 |
| Leguy-Seguin, V | 2 |
| Berthier, S | 2 |
| Bonnotte, B | 3 |
| Audia, S | 3 |
| Depré, F | 1 |
| Aboud, N | 1 |
| Mayer, B | 1 |
| Salama, A | 1 |
| Rodrigo, C | 1 |
| Gooneratne, L | 1 |
| Patel, AP | 1 |
| Patil, AS | 1 |
| Oo, T | 1 |
| Hill, QA | 2 |
| Sauvetre, G | 1 |
| MahÉvas, M | 2 |
| Limal, N | 1 |
| Guillaud, C | 1 |
| Khellaf, M | 1 |
| Bierling, P | 4 |
| Languille, L | 1 |
| Delbos, F | 1 |
| Noizat-Pirenne, F | 1 |
| Michel, M | 2 |
| Godeau, B | 6 |
| Ali, M | 1 |
| Islam, MS | 1 |
| Rahman, MH | 1 |
| Islam, MM | 1 |
| Anis, MA | 1 |
| Vancine-Califani, SM | 1 |
| Ozelo, MC | 1 |
| Orsi, FL | 1 |
| Fabri, DR | 1 |
| Varghese, L | 1 |
| Viswabandya, A | 2 |
| Mathew, AJ | 1 |
| Vizcaíno, G | 1 |
| Diez-Ewald, M | 1 |
| Vizcaíno-Carruyo, J | 1 |
| Lakomy, D | 1 |
| Guy, J | 1 |
| Aho, S | 1 |
| Lorcerie, B | 1 |
| Zaja, F | 1 |
| Marin, L | 1 |
| Chiozzotto, M | 1 |
| Puglisi, S | 1 |
| Volpetti, S | 1 |
| Fanin, R | 1 |
| Pusiol, A | 1 |
| Nocerino, A | 1 |
| Passone, E | 1 |
| Tenore, A | 1 |
| Treppendahl, MB | 1 |
| Nielsen, OJ | 1 |
| Damodar, S | 1 |
| George, B | 1 |
| Mathews, V | 1 |
| Chandy, M | 1 |
| Srivastava, A | 1 |
| Schiff, DE | 1 |
| Roberts, WD | 1 |
| Sue, YJ | 1 |
| Litton, G | 1 |
| Hernández, F | 1 |
| Linares, M | 2 |
| Colomina, P | 2 |
| Pastor, E | 2 |
| Cerveró, A | 2 |
| Pérez, A | 1 |
| Perella, M | 1 |
| Oksenhendler, E | 2 |
| Durand, JM | 1 |
| Roudot-Thoraval, F | 1 |
| Tennezé, A | 1 |
| Kaplanski, G | 1 |
| Schaeffer, A | 1 |
| Radaelli, F | 1 |
| Calori, R | 1 |
| Goldaniga, M | 1 |
| Guggiari, E | 1 |
| Luciano, A | 1 |
| Tsujimoto, S | 1 |
| Inami, M | 1 |
| Matsumoto, S | 1 |
| Naoe, Y | 1 |
| Kawamura, I | 1 |
| Shimomura, K | 1 |
| Hirasawa, A | 1 |
| Sato, T | 1 |
| Kawabuchi, Y | 1 |
| Nishikawa, T | 1 |
| Chiba, S | 1 |
| Wakabayashi, Y | 1 |
| Le Louët, H | 1 |
| Ruivart, M | 1 |
| Duche, JC | 1 |
| Lush, R | 1 |
| Iland, H | 1 |
| Peat, B | 1 |
| Young, G | 1 |
| Kurata, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia[NCT02627417] | Phase 3 | 216 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia[NCT02575235] | Early Phase 1 | 100 participants (Actual) | Interventional | 2015-10-01 | Completed | ||
| Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia: An Exploratory Pilot Study[NCT02297997] | Early Phase 1 | 65 participants (Actual) | Interventional | 2014-11-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for dapsone and Autoimmune Thrombocytopenia
| Article | Year |
|---|---|
Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Child; Clinical Trials as Topic; Dapsone; Evide | 2013 |
How does dapsone work in immune thrombocytopenia? Implications for dosing.
Topics: Anti-Infective Agents; Dapsone; Female; Humans; Male; Purpura, Thrombocytopenic, Idiopathic | 2015 |
How we manage immune thrombocytopenia in the elderly.
Topics: Aged; Aged, 80 and over; Danazol; Dapsone; Disease Management; Female; Humans; Immunoglobulins, Intr | 2016 |
[Treatment of chronic immune thrombocytopenic purpura. Looking for something better. Review].
Topics: Adrenal Cortex Hormones; Antigens, Human Platelet; Autoantibodies; Benzoates; Blood Platelets; Clini | 2009 |
[New development in the treatment of idiopathic thrombocytopenic purpura].
Topics: Antibodies, Monoclonal; CD40 Ligand; Dapsone; Humans; Laparoscopy; Membrane Glycoproteins; Purpura, | 2000 |
3 trials available for dapsone and Autoimmune Thrombocytopenia
| Article | Year |
|---|---|
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Contraindications; Dan | 2012 |
Dapsone for autoimmune thrombocytopenic purpura.
Topics: Adult; Aged; Dapsone; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet | 1993 |
[Diaminodiphenyl sulfone therapy for refractory idiopathic thrombocytopenic purpura--long-term effectiveness and possible mechanisms].
Topics: Administration, Oral; Adult; Dapsone; Dose-Response Relationship, Drug; Female; Humans; Leprostatic | 1999 |
27 other studies available for dapsone and Autoimmune Thrombocytopenia
| Article | Year |
|---|---|
Synthesis and effects of novel thiazole derivatives against thrombocytopenia.
Topics: Animals; Autoantibodies; Blood Platelets; Dapsone; Disease Models, Animal; Dose-Response Relationshi | 1998 |
Is dapsone still relevant in immune thrombocytopenia in resource limited settings?
Topics: Adult; Dapsone; Diagnosis, Differential; Gingival Hemorrhage; Humans; India; Male; Medically Underse | 2019 |
Combination Therapy of Azathioprine+ Dapsone as Effective Second Line Agents for the Treatment of Chronic Immune Thrombocytopenic Purpura.
Topics: Anti-Infective Agents; Azathioprine; Combined Modality Therapy; Dapsone; Humans; Immunosuppressive A | 2020 |
Dapsone Induced Agranulocytosis and Hemolytic Anemia in Immune Thrombocytopenic Purpura.
Topics: Agranulocytosis; Anemia, Hemolytic; Dapsone; Humans; Purpura; Purpura, Thrombocytopenic; Purpura, Th | 2020 |
A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: Efficacy, safety and factors associated with treatment response.
Topics: Dapsone; Humans; Purpura, Thrombocytopenic, Idiopathic; Remission Induction; Retrospective Studies; | 2021 |
Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients.
Topics: Adult; Dapsone; Humans; Purpura, Thrombocytopenic, Idiopathic; Retrospective Studies | 2017 |
Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Benzoates; Child; Child, Preschool; Combin | 2018 |
Dapsone for immune thrombocytopenic purpura in children and adults.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Dapsone; Erythrocyte Indices; Female; Follow-Up St | 2015 |
Disappointing response to dapsone as second line therapy for primary ITP: a case series.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dapsone; Female; Humans; Male; Middle Aged; Purpura, Thr | 2015 |
Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases.
Topics: Adult; Anti-Infective Agents; Dapsone; Drug Hypersensitivity; Exanthema; Female; Humans; Male; Purpu | 2015 |
Is there still a place for "old therapies" in the management of immune thrombocytopenia?
Topics: Benzoates; Danazol; Dapsone; Humans; Hydrazines; Hydroxychloroquine; Immunoglobulins, Intravenous; P | 2016 |
Response of Dapsone in Refractory Chronic Immune Thrombocytopenia.
Topics: Dapsone; Humans; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Treatme | 2016 |
Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Cohort Studies; Dapsone; Drug-Related Side Effects and Adverse Reactions; F | 2008 |
Dapsone, danazol, and intrapartum splenectomy in refractory ITP complicating pregnancy.
Topics: Anti-Inflammatory Agents; Cesarean Section; Danazol; Dapsone; Dexamethasone; Estrogen Antagonists; F | 2008 |
[Treatment of immune thrombocytopenia: a retrospective study of 40 patients].
Topics: Adult; Aged; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; | 2010 |
Dapsone treatment in a girl with severe chronic thrombocytopenic purpura. Does it work? Do not touch it!
Topics: Adolescent; Blood Platelets; Dapsone; Female; Humans; Intracranial Hemorrhages; Platelet Count; Purp | 2012 |
[Idiopathic thrombocytopenic purpura. A retrospective evaluation of 68 patients].
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Azathioprine; Cyclophospha | 2004 |
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chronic Disease; Dapsone; Drug Evaluation; | 2005 |
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chronic Disease; Dapsone; Drug Evaluation; | 2005 |
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chronic Disease; Dapsone; Drug Evaluation; | 2005 |
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chronic Disease; Dapsone; Drug Evaluation; | 2005 |
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chronic Disease; Dapsone; Drug Evaluation; | 2005 |
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chronic Disease; Dapsone; Drug Evaluation; | 2005 |
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chronic Disease; Dapsone; Drug Evaluation; | 2005 |
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chronic Disease; Dapsone; Drug Evaluation; | 2005 |
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chronic Disease; Dapsone; Drug Evaluation; | 2005 |
Methemoglobinemia associated with dapsone therapy in a child with pneumonia and chronic immune thrombocytopenic purpura.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Mur | 2006 |
Refractory idiopathic thrombocytopenic purpura treated with the soluble tumor necrosis factor receptor etanercept.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Colchicine; Combined Modality | 2008 |
Dapsone for refractory chronic idiopathic thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Dapsone; Female; Humans; Middle Aged; P | 1995 |
Dapsone for idiopathic thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Dapsone; Female; Humans; Male; Middle Aged; Purpura, Thrombocytopenic, Idio | 1994 |
Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases.
Topics: Adult; Chronic Disease; Dapsone; Female; Humans; Male; Middle Aged; Platelet Count; Purpura, Thrombo | 1997 |
Adult refractory chronic idiopathic thrombocytopenic purpura: can dapsone be proposed as second-line therapy?
Topics: Aged; Chronic Disease; Dapsone; Female; Humans; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopa | 1999 |
Effects of a novel pyridylsulphonyl thiazole derivative, FR115092, on autoimmune and mitomycin C-induced thrombocytopenia in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Autoimmunity; Blood Platelets; Bon | 1999 |
Lack of relevance of the acetylator status on dapsone response in chronic autoimmune thrombocytopenic purpura.
Topics: Acetylation; Arylamine N-Acetyltransferase; Dapsone; Female; Humans; Male; Middle Aged; Phenotype; P | 1999 |
Successful use of dapsone in refractory pregnancy-associated idiopathic thrombocytopenic purpura.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dapsone; Female; Glucocorticoids; Humans; Immunoglob | 2000 |